A Look At BioCryst Pharmaceuticals (BCRX) Valuation After New R&D Leadership Appointment

Simply Wall St.04-09

BioCryst Pharmaceuticals (BCRX) is in focus after appointing Sandeep M. Menon as Chief Research and Development Officer, a leadership change that directly ties to its rare disease pipeline and longer ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626925512?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-09 00:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626925512","market":"hk","top_or_hot":-1,"title":"A Look At BioCryst Pharmaceuticals (BCRX) Valuation After New R&D Leadership Appointment","media":"Simply Wall St.","content":"<div>\n<p>BioCryst Pharmaceuticals (BCRX) is in focus after appointing Sandeep M. Menon as Chief Research and Development Officer, a leadership change that directly ties to its rare disease pipeline and longer ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/a-look-at-biocryst-pharmaceuticals-bcrx-valuation-after-new-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At BioCryst Pharmaceuticals (BCRX) Valuation After New R&D Leadership Appointment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At BioCryst Pharmaceuticals (BCRX) Valuation After New R&D Leadership Appointment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-09 00:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/a-look-at-biocryst-pharmaceuticals-bcrx-valuation-after-new-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioCryst Pharmaceuticals (BCRX) is in focus after appointing Sandeep M. Menon as Chief Research and Development Officer, a leadership change that directly ties to its rare disease pipeline and longer ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/a-look-at-biocryst-pharmaceuticals-bcrx-valuation-after-new-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4547","symbol_name":"WSB热门概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/a-look-at-biocryst-pharmaceuticals-bcrx-valuation-after-new-1","article_id":"2626925512","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/a-look-at-biocryst-pharmaceuticals-bcrx-valuation-after-new-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2626925512","pubTimestamp":1775665137,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BioCryst Pharmaceuticals (BCRX) is in focus after appointing Sandeep M. Menon as Chief Research and Development Officer, a leadership change that directly ties to its rare disease pipeline and longer term R&D priorities.\nSee our latest analysis for BioCryst Pharmaceuticals.\nAt a share price of $9.59, BioCryst has seen a 30 day share price return of 13.09% and year to date share price return of 27.87%, while the 1 year total shareholder return of 48.22% points to building momentum around...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4547":"WSB热门概念","BCRX":"BioCryst制药","BK4139":"生物科技"},"translate_title":"新研发领导层任命后BioCryst Pharmaceuticals(BCRX)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCRX":1.5},"content_text":"BioCryst Pharmaceuticals (BCRX) is in focus after appointing Sandeep M. Menon as Chief Research and Development Officer, a leadership change that directly ties to its rare disease pipeline and longer term R&D priorities. See our latest analysis for BioCryst Pharmaceuticals. At a share price of $9.59, BioCryst has seen a 30 day share price return of 13.09% and year to date share price return of 27.87%, while the 1 year total shareholder return of 48.22% points to building momentum around recent R&D updates and leadership changes. If this kind of rare disease story has your attention, it could be a good moment to widen your search with other health focused AI names through the 37 healthcare AI stocks With shares at $9.59 and management highlighting a rare disease pipeline, the big question is whether BioCryst’s current valuation still leaves meaningful upside on the table or if the market is already pricing in future growth. AdvertisementMost Popular Narrative: 55% Undervalued With shares at $9.59 against a narrative fair value of $21.30, the gap between market price and expectations is wide enough to matter for anyone following BioCryst closely.  Strong and sustainable revenue growth for ORLADEYO, supported by increasing new patient prescriptions, expanding prescriber base, and robust retention rates, positions BioCryst to capitalize on the rising prevalence and earlier diagnosis of rare diseases, likely driving sustained top-line expansion and improved profit margins.  Read the complete narrative. Want to see what underpins that confidence in future cash flows and margins? The narrative leans on specific revenue paths, profitability shifts and a punchy future earnings multiple that most investors would not guess from today’s share price. Result: Fair Value of $21.30 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on ORLADEYO staying on track and pipeline assets like BCX17725 and navenibart hitting key milestones without clinical or competitive setbacks. Find out about the key risks to this BioCryst Pharmaceuticals narrative. Next Steps With sentiment split between opportunity and concern, this is a good moment to move quickly, test the assumptions yourself, and weigh up the 4 key rewards and 3 important warning signs Ready for more investment ideas? If BioCryst has sparked your curiosity, do not stop here. Broaden your watchlist with other focused stock ideas surfaced through Simply Wall Street’s data driven screeners.  Target potential mispricings by scanning a focused set of quality candidates using the 61 high quality undervalued stocks. Prioritise capital preservation while still hunting for opportunities through the 70 resilient stocks with low risk scores. Hunt for names that many investors may be overlooking by checking the screener containing 24 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if BioCryst Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626925512","isCrawlerRequest":true}